FDA new draft guidance: Post-warning letter meetings under GDUFA

2 September 2023
fda_food_and_drug_administration_large

The US Food and Drug Administration (FDA) on Friday announced a draft guidance for industry, “ Post-Warning Letter Meetings Under GDUFA.”

The guidance provides information on the implementation of the post-warning letter meeting process for certain drug manufacturing facilities, a program enhancement agreed upon by the agency and industry as part of the negotiations relating to the reauthorization of the  Generic Drug User Fee Amendments (GDUFA), as described in “GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027” ( GDUFA III commitment letter).

Specifically, this draft guidance describes:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics